Can CT-PET and Endoscopic Assessment Post-Neoadjuvant Chemoradiotherapy Predict Residual Disease in Esophageal Cancer?
Can CT-PET and Endoscopic Assessment Post-Neoadjuvant Chemoradiotherapy Predict Residual Disease in Esophageal Cancer?
复制标题
DOI：
10.1097/sla.0000000000001902
复制
发表时间：
2016-11-01
影响因子：
9
通讯作者：
Reynolds, John V.
中科院分区：
文献类型：
--
作者：
Heneghan, Helen M.;Donohoe, Claire;Reynolds, John V.
目的：本研究的目的是评估CT-PET和内镜评估后新辅助放化疗（nCRT）在预测完全病理反应（pCR）在局部晚期食管癌（LAEC.Design）：前瞻性队列研究。背景：nCRT是越来越多的标准治疗LAEC，与pCR的替代优良的结果。术前预测pCR，代谢成像和内窥镜检查，可能会节省患者的手术intervention.Methods：138例连续患者[平均年龄618岁，99名男性（72%），103（75%）腺癌]接受nCRT与CT-PET和内窥镜检查4至6周后，手术随后。完全代谢反应（cMR）定义为SUVmax
Objective:The aim of this study is to assess CT-PET and endoscopic assessment postneoadjuvant chemoradiotherapy (nCRT) in predicting complete pathologic response (pCR) in locally advanced esophageal cancer (LAEC).Design:A prospective cohort study.Background:nCRT is increasingly standard of care in LAEC, with pCR a surrogate for excellent outcome. Predicting pCR before surgery, with metabolic imaging and endoscopy, may spare patients' operative intervention.Methods:One hundred thirty-eight consecutive patients [mean age 618, 99 male (72%), 103 (75%) adenocarcinoma] underwent nCRT with CT-PET and endoscopy 4 to 6 weeks later, and surgery subsequently. A complete metabolic response (cMR) was defined as SUVmax of